108 related articles for article (PubMed ID: 15217162)
1. Absenteeism among employees with irritable bowel syndrome.
Zacker C; Chawla AJ; Wang S; Albers LA
Manag Care Interface; 2004 May; 17(5):28-32. PubMed ID: 15217162
[TBL] [Abstract][Full Text] [Related]
2. Impairment in work productivity and health-related quality of life in patients with IBS.
Dean BB; Aguilar D; Barghout V; Kahler KH; Frech F; Groves D; Ofman JJ
Am J Manag Care; 2005 Apr; 11(1 Suppl):S17-26. PubMed ID: 15926760
[TBL] [Abstract][Full Text] [Related]
3. Total costs of IBS: employer and managed care perspective.
Cash B; Sullivan S; Barghout V
Am J Manag Care; 2005 Apr; 11(1 Suppl):S7-16. PubMed ID: 15926759
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study.
Paré P; Gray J; Lam S; Balshaw R; Khorasheh S; Barbeau M; Kelly S; McBurney CR
Clin Ther; 2006 Oct; 28(10):1726-35; discussion 1710-1. PubMed ID: 17157129
[TBL] [Abstract][Full Text] [Related]
5. Daily stress and gastrointestinal symptoms in women with irritable bowel syndrome.
Hertig VL; Cain KC; Jarrett ME; Burr RL; Heitkemper MM
Nurs Res; 2007; 56(6):399-406. PubMed ID: 18004186
[TBL] [Abstract][Full Text] [Related]
6. Tegaserod treatment for IBS: a model of indirect costs.
Smith DG; Barghout V; Kahler KH
Am J Manag Care; 2005 Apr; 11(1 Suppl):S43-50. PubMed ID: 15926763
[TBL] [Abstract][Full Text] [Related]
7. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome?
Burgmann T; Clara I; Graff L; Walker J; Lix L; Rawsthorne P; McPhail C; Rogala L; Miller N; Bernstein CN
Clin Gastroenterol Hepatol; 2006 May; 4(5):614-20. PubMed ID: 16630762
[TBL] [Abstract][Full Text] [Related]
8. Budget impact of tegaserod on a managed care organization formulary.
Bloom MA; Barghout V; Kahler KH; Bentkover J; Kurth H; Gralnek IM; Spiegel BM
Am J Manag Care; 2005 Apr; 11(1 Suppl):S27-34. PubMed ID: 15926761
[TBL] [Abstract][Full Text] [Related]
9. Hypervigilance in irritable bowel syndrome compared with organic gastrointestinal disease.
Posserud I; Svedlund J; Wallin J; Simrén M
J Psychosom Res; 2009 May; 66(5):399-405. PubMed ID: 19379956
[TBL] [Abstract][Full Text] [Related]
10. Physicians' attitudes and practices in the evaluation and treatment of irritable bowel syndrome.
Lacy BE; Rosemore J; Robertson D; Corbin DA; Grau M; Crowell MD
Scand J Gastroenterol; 2006 Aug; 41(8):892-902. PubMed ID: 16803687
[TBL] [Abstract][Full Text] [Related]
11. The spectrum of irritable bowel syndrome: A clinical review.
Gilkin RJ
Clin Ther; 2005 Nov; 27(11):1696-709. PubMed ID: 16368443
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome.
Tillisch K; Labus JS; Naliboff BD; Bolus R; Shetzline M; Mayer EA; Chang L
Am J Gastroenterol; 2005 Apr; 100(4):896-904. PubMed ID: 15784038
[TBL] [Abstract][Full Text] [Related]
13. Comorbidity in irritable bowel syndrome.
Whitehead WE; Palsson OS; Levy RR; Feld AD; Turner M; Von Korff M
Am J Gastroenterol; 2007 Dec; 102(12):2767-76. PubMed ID: 17900326
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
15. Comorbidity and use of health-care services among irritable bowel syndrome sufferers.
Hillilä MT; Siivola MT; Färkkilä MA
Scand J Gastroenterol; 2007 Jul; 42(7):799-806. PubMed ID: 17558902
[TBL] [Abstract][Full Text] [Related]
16. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire--irritable bowel syndrome version (WPAI:IBS).
Reilly MC; Bracco A; Ricci JF; Santoro J; Stevens T
Aliment Pharmacol Ther; 2004 Aug; 20(4):459-67. PubMed ID: 15298641
[TBL] [Abstract][Full Text] [Related]
17. Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study.
Brun-Strang C; Dapoigny M; Lafuma A; Wainsten JP; Fagnani F
Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1097-103. PubMed ID: 17998835
[TBL] [Abstract][Full Text] [Related]
18. Different segmental transit times in patients with irritable bowel syndrome and "normal" colonic transit time: is there a correlation with symptoms?
Bouchoucha M; Devroede G; Dorval E; Faye A; Arhan P; Arsac M
Tech Coloproctol; 2006 Dec; 10(4):287-96. PubMed ID: 17115321
[TBL] [Abstract][Full Text] [Related]
19. A population-based case-control study of work and psychosocial problems in patients with irritable bowel syndrome--women are more seriously affected than men.
Faresjö A; Grodzinsky E; Johansson S; Wallander MA; Timpka T; Akerlind I
Am J Gastroenterol; 2007 Feb; 102(2):371-9. PubMed ID: 17156145
[TBL] [Abstract][Full Text] [Related]
20. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities.
Ruigómez A; García Rodríguez LA; Panés J
Clin Gastroenterol Hepatol; 2007 Apr; 5(4):465-9. PubMed ID: 17445753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
